Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by BioHealth Innovation, Inc. (BHI), BioHealth Innovation, and Inc. (BHI). All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BioHealth Innovation, Inc. (BHI), BioHealth Innovation, and Inc. (BHI) or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Inside CTMC: Amy Hay on Reshaping Cell and Gene Therapy

39:23
 
Share
 

Manage episode 488447614 series 1551347
Content provided by BioHealth Innovation, Inc. (BHI), BioHealth Innovation, and Inc. (BHI). All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BioHealth Innovation, Inc. (BHI), BioHealth Innovation, and Inc. (BHI) or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

In this episode of BioTalk, Amy C. Hay, Chief Business and Strategy Officer at the Cell Therapy Manufacturing Center (CTMC), joins the conversation to explore the evolving landscape of cell and gene therapy. Amy shares insights from her extensive career in oncology care and innovation, highlighting the role CTMC—a joint venture between National Resilience and MD Anderson Cancer Center—is playing in accelerating the transition from discovery to commercialization. She discusses the current state of the industry, what disruption really means in this context, and how new business models can drive stability and impact for early-stage biotech companies. Amy also offers her perspective on how manufacturing must evolve to meet clinical demand, and how CTMC is positioned to lead in this next era of therapeutic development.

Editing and post-production work for this episode was provided by The Podcast Consultant.

Amy C. Hay is the Chief Business and Strategy Officer at the Cell Therapy Manufacturing Center (CTMC), a joint venture between National Resilience and MD Anderson Cancer Center. She brings decades of experience in oncology care, strategic growth, and healthcare innovation to her role, where she leads business strategy, partnerships, and long-term growth initiatives. Prior to CTMC, Amy held leadership roles at Varian (a Siemens Healthineers company), MD Anderson Cancer Center, and several global consulting efforts focused on advancing cancer care. Her career spans work across the U.S. and internationally, with a focus on driving innovation, commercialization, and patient access in complex health systems.

  continue reading

180 episodes

Artwork
iconShare
 
Manage episode 488447614 series 1551347
Content provided by BioHealth Innovation, Inc. (BHI), BioHealth Innovation, and Inc. (BHI). All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BioHealth Innovation, Inc. (BHI), BioHealth Innovation, and Inc. (BHI) or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

In this episode of BioTalk, Amy C. Hay, Chief Business and Strategy Officer at the Cell Therapy Manufacturing Center (CTMC), joins the conversation to explore the evolving landscape of cell and gene therapy. Amy shares insights from her extensive career in oncology care and innovation, highlighting the role CTMC—a joint venture between National Resilience and MD Anderson Cancer Center—is playing in accelerating the transition from discovery to commercialization. She discusses the current state of the industry, what disruption really means in this context, and how new business models can drive stability and impact for early-stage biotech companies. Amy also offers her perspective on how manufacturing must evolve to meet clinical demand, and how CTMC is positioned to lead in this next era of therapeutic development.

Editing and post-production work for this episode was provided by The Podcast Consultant.

Amy C. Hay is the Chief Business and Strategy Officer at the Cell Therapy Manufacturing Center (CTMC), a joint venture between National Resilience and MD Anderson Cancer Center. She brings decades of experience in oncology care, strategic growth, and healthcare innovation to her role, where she leads business strategy, partnerships, and long-term growth initiatives. Prior to CTMC, Amy held leadership roles at Varian (a Siemens Healthineers company), MD Anderson Cancer Center, and several global consulting efforts focused on advancing cancer care. Her career spans work across the U.S. and internationally, with a focus on driving innovation, commercialization, and patient access in complex health systems.

  continue reading

180 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play